Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Hematol. 2007;86(3): 212-215.Aessopos, A. , Kati, M. , Farmaki, D. , Polonifi, E. , Deftereos, S. & Tsironi, M. ( 2007 ) Intensive chelation therapy in β-thalassemia ...
No adverse effects on maternal reproductive function or on the development of the offspring (F1) were observed at doses up to 20 mg/kg/day (2 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and similar to the human clinical exposure based on AUC in ...
chelationtherapyAdverseeffectsMuscularweaknessDeferasiroxDeferasirox is a standard treatment for chronic transfusional iron overload. Adverse effects of deferasirox have been reported in large prospective studies. We report two cases of monozygotic twins manifesting with proximal muscular atrophy and weakness ...
To date, management of transfusional iron overload has consisted of chelation therapy with parenteral deferoxamine. Although survival rates improve with adequate chelation, an estimated one third to one half of patients are not compliant with deferoxamine therapy, largely because of the discomfort and ...
Systemic and topical steroid therapy was started after termination of chelation therapy and lesions regressed with steroids. Discussion Drug eruptions are substantially common dermatological problems and can be seen in about 2.2% of inpatients. The most common unexpected effects of DMPS are allergic skin...
Reversing the adverse biochemical effects in lead-intoxicated rats by N , N` - bis [(1,2-didehydro-1-hydroxy-2-thioxopyrid-4-yl)-carbonyl]- L -lysineChelation therapySubchronic lead poisoningUrinary proporphyrinsAminolevulinic acid dehydratase...